POLYAMINES IN PROSTATE CANCER: THE RELATIONSHIP WITH THE AGGRESSIVENESS OF TUMORS AND THE RISK OF DISEASE PROGRESSION

S.P. Zaletok¹, O.O. Klenov¹, V.V. Bentrad¹, M.P. Prylutskyi¹, Yu.V. Yanish¹, Yu.V. Vitruk², E.О. Stakhovsky²

¹ R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, NAS of Ukraine
² National Cancer Institute, Kyiv, Ukraine

DOI: https://doi.org/10.15407/oncology.2023.02.128

Summary. Altered metabolism is one of the key molecular characteristics of prostate cancer (PCa). The search for new tissue biomarkers that could be used for diagnosis, assessment of aggressiveness and risk of progression of PCa is an urgent problem. In this regard, polyamines (PA) — spermine (Spn), spermidine, putrescine — substances necessary for cell proliferation and growth deserve special attention. Aim: to investigate PA levels in postoperative and biopsy specimens of benign and malignant human prostate tumors to determine the potential for their use for more accurate differential diagnosis, assessment of the aggressiveness of PCa and the risk of disease progression. Object and methods: the study was conducted on 120 postoperative samples from patients with PCa (n = 100) and with benign prostatic hyperplasia (BHP, n = 20), as well as on 40 samples obtained in multifocal trepanbiopsy of prostate (20 samples of malignant tissue and 20 samples of benign tumor tissue). The method of highperformance liquid chromatography (HPLC) was used to determine PA. Statistical processing of the results was carried out by the methods of variational statistics using standard licensed computer programs STATISTICA 6.0, Microsoft Excel. The significance of the differences between indicators in different groups was assessed using the Student’s t-test. Differences were considered significant at p < 0.05. Spearman’s correlation coefficients were calculated to identify correlative relationships between the studied indicators. Results: it was established that in prostatic hyperplasia, PA levels are significantly higher than those in malignant tumors of the prostate. The most significant difference between PCa and BHP was observed for Spn. The relationship between the level of Spn and the histological evaluation of the differentiation of the PCa according to the Gleason Score and the risk of disease progression was established. Conclusions: the inverse relationship of Spn levels with the degree of differentiation of tumors according to the Gleason Score and the risk of disease progression indicate the participation of spermine in the formation of the aggressiveness of prostate cancer and demonstrate the perspective of its use as an additional tissue marker for the differential diagnosis of prostate tumors, assessment of the malignancy of prostate cancer and the risk of disease progression.

References

1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statis- tics CA: A Cancer J Clinicians 2022; 72 (1): 7–33. https://doi.org/10.3322/caac.21708.
2. Bernard B, Burnett C, Sweeney CJ, et al. Impact of age at diagnosis of de novo metastatic prostate cancer on Cancer 2020; 126 (5), 986–93. https://doi.org/10.1002/ cncr.32630.
3. Fedorenko Z, Sumkina O, Goroh Ye, et al. Cancer in Ukraine, 2020–2021. Morbidity, mortality, performance indicators of the oncology service. Bull Natl Cancer Reg Ukr; Kyiv; 2022; 23: 132 http://www.ncru.inf.ua/publications/BULL_23/PDF/BULL_23.pdf (in Ukrainian).
4. Pavlova NN, Thompson The emerging hallmarks of cancer metabolism. Cell Metab 2016; 23: 27–47. https:// doi.org/10.1016/j.cmet.2015.12.006.
5. Cheung PK, Ma MH, Tse HF, et al. The applications of metabolomics in the molecular diagnostics of Expert Rev Mol Diagn 2019; 19 (1): 785–93. doi.org/10.1080/ 14737159.2019.1656530.
6. Gómez-Cebrián N, Poveda JL, Pineda-Lucena A, Puchades- Carrasco Metabolic phenotyping in prostate cancer using multi-omics approaches. Cancers (Basel) 2022; 14 (3): 596. doi: 10.3390/cancers14030596.
7. Vander Heiden MG, Lunt SY, Dayton TL, et al. Metabolic pathway alterations that support cell proliferati Cold Spring Harb Symp Quant Biol 2011; 76: 325–334. doi: 10. 1101/sqb.2012.76.010900.
8. Harris Development of cancer metabolism as a thera- peutic target: new pathways, patient studies, stratifi ation and combination therapy. Br J Cancer 2020; 122: 1–3. doi: 10.1038/s41416-019-0666-4.
9. Lyssiotis CA, Nagrath D. Metabolic reprogramming and vulnerabilities in cance Cancers 2019; 12: 90. doi: 10. 3390/cancers12010090.
10. Stine ZE, Schug ZT, Salvino JM, Dang Targeting cancer metabolism in the era of precision oncology. Nat Rev Drug Discov 2021; 3: 2–22. doi: 10.1038/s41573-021- 00339-6.
11. Cancer: prediction, diagnosis, progression, prognosis, and recurren Cancer Epidemiol Biomarkers Prev 2016; 25 (6): 887–906. https://doi.org/10.1158/1055-9965.EPI-15- 1223.
12. Lima AR, Bastos Mde L, Carvalho M, et al. Biomarker dis- covery in human prostate cancer: an update in metabolom- ics stu Transl Oncol 2016; 9 (4): 357–70. https://doi. org/10.1016/j.tranon.2016.05.004.
13. Lin Y, Zhao X, Miao Z, et al. Data–driven translational prostate cancer research: from biomarker discovery to clini- cal decis J Transl Med 2020; 18: 119–36. doi: 10.1186/ s12967-020-02281-4.
14. Kdadra M, Höckner S, Leung H, et al. Metabolomics bio- markers of prostate cancer: a systematic review. Diag- nostics (Basel) 2019; 9: 21–65. doi: 3390/diagnostics 9010021.
15. Zadvornyi ТV, Borikun TV, Lukianova NYu, et al. Expression of miRNA–126, –205 AND –214 in benign and malignant neoplasms of the prostate gland: possible diagnostic and prognostic signifi an Oncology 2019; 21 (1): 10–6. doi: 10.32471/oncology.2663–7928.t–21–3–2019–g.7695. (in Ukrainian).
16. Polyamin A Universal molecular nexus for growth, sur- vival, and specialized metabolism. Kusano T, Suzuki H. (eds). Springer 2015: 330 p. ISBN-10: 4431552111.
17. Igarashi K, Kashiwagi K. The functional role of polyamines in eukaryotic Int J Biochem Cell Biol 2019; 107: 104–15. https://doi.org/10.1016/j.biocel.2018.12.012.
18. Igarashi K, Kashiwagi K. Functional roles of polyamines and their metabolite acrolein in eukaryotic Amino Acids 2021; 53: 1473–92. https://doi.org/10.1007/s00726-021- 03073-w.
19. Zahedi K, Barone S, and Soleimani Polyamines and their metabolism: from the maintenance of physiologi- cal homeostasis to the mediation of disease. Medical Sci- ences 2022; 10 (3): 38. https://doi.org/10.3390/medsci 10030038.
20. Childs AC, Mehta DJ, Gerner EW. Polyamine–dependent gene express Cell Mol Life Sci 2003; 60 (7):1394–406. doi: 10.1007/s00018-003-2332-4.
21. Li J, Meng Y, Wu X, et al. Polyamines and related signaling pathways in cance Cancer Cell Int 2020; 20: 539. doi: 10.1186/s12935–020–01545–9.
22. Bachmann AS, Geerts Polyamine synthesis as a target of MYC oncogenes. J Biol Chem. 2018; 293 (48): 18757–69. doi: 10.1074/jbc.TM118.003336.
23. Guo Yu, Ye Q, Deng P, et al. Spermine synthase and MYC cooperate to maintain colorectal cancer cell survival by repressing Bim express Nat Commun 2020; 11: 3243. doi: 10.1038/s41467-020-17067-x.
24. Berdinskikh NK. Zaletok SP. Poliaminy i opukholevyi ros Kiyv: Nauk. dumka, 1987. 140 p. (in Russian).
25. Zaletok The role of polyamines in carcinogenesis and tumor growth. In: Onkolohiya. Lektsiyi. Chekhun VF (eds). K: Zdorov’ya Ukrayiny, 2010: 354–70. (in Ukrainian).
26. Casero RA Jr, Murray Stewart T, Pegg Polyamine me- tabolism and cancer: treatments, challenges and opportuni- ties. Nat Rev Cancer 2018; 18 (11): 681–95. doi: 10.1038/ s41568-018-0050-3.
27. Cohen A guide to the polyamines. NY: Oxford Univ Press, 1998: 240 p.
28. Harrison GA. Spermine in human t Biochem J 1931; CCII: 1885–92.
29. Harrison GA. CL The approximate determination of spermine in single human organs. Biochem J 1933; CLIII: 1152–6.
30. Palavan-Unsal, Aloglu-Senturk SM,. Arısan The function of polyamine metabolism in prostate cancer. Exp. Oncol 2006; 28: 178–86.
31. Shukla-Dave A, Castillo-Martin M, Chen M, et al. Ornithine decarboxylase is suffi ient for prostate tumorigenesis via androgen receptor Am J Pathol 2016; 186 (12): 3131–45. doi: 10.1016/j.ajpath.2016.08.021.
32. Huang W, Eickhoff JC, Mehraein-Ghomi F, et al. Expression of spermidine/spermine N1-acetyl transferase (SSAT) in human prostate tissues is related to prostate cancer pro- gression and metast Prostate 2015; 75: 1150–9. doi: 10.1002/pros.22996.
33. Zabala-Letona A, Arruabarrena-Aristorena A, Martín-Mar- tín N, et al. mTORC1–dependent AMD1 regulation sustains Polyamine metabolism in prostate cance Nature 2017; 547 (7661): 109–13. doi: 10.1038/nature22964.
34. Smith R, Litwin M, Lu Y, Zetter Identifi ation of an en- dogenous inhibitor of prostate carcinoma cell growth. Na- ture Med 1995; 1: 1040–5. doi: 10.1038/nm1095-1040.
35. Koike C, Chao DT, and Zetter Sensitivity to polyamine- induced growth arrest correlates with  antizyme  induc- tion in prostate carcinoma cells. Cancer Res 1999; 59: 6109–12.
36. Andersen MK, Giskeødegård GF, Tessem M-B. Metabolic alterations in tissues and biofl of prostate cancer pa- Curr Opin Endocr Metab Res 2020; 10: 23–8. doi: 10.1016/j.coemr.2020.02.003
37. Zaletok S, Klenov O, Bentrad V, et al. Polyamines as new potential biomarkers for differential diagnosis of prostate cancer and estimation of its Exp Oncol 2022; 44 (2): 148–154. doi: 10.32471/exp-oncology.2312-8852. vol-44-no-2.17758.
38. Pérez-Riesgo E, Hernando-Pérez E, Feij V, et al. Trans- criptional basis of Ca2+remodeling reversal induced by polyamine synthesis inhibition in colorectal cancer cells. Cancers (Basel) 2023; 15 (5): doi: 10.3390/cancers 15051600.
39. Meyskens F, Simoneau A, Gerner Chemoprevention of prostate cancer with the polyamine synthesis inhibitor di- fl oromethylornithine. Recent Results Cancer Res 2014; 202: 115–120. doi: 10.1007/978-3-642-45195-9_14.
40. Gerbaut Determination of erythrocytic polyamines by reversed-phase liquid chromatography. Clin Chem 1991; 37: 2117–20.
41. Lakin GF. M: Vysshaya shkola 1990: 352 p. (in Russian).
42. Gubler EV, Genkin AA. Application of non-parametric cri- teria of statistics in medical and biological Lenin- grad 1973: 141 p. (in Russian).
43. Tessem MB, Bertilsson H, Angelsen А, et al. A Balanced tis- sue composition reveals new metabolic and gene expression markers in prostate PLoS One 2016; 11: e0153727. doi: 10.1371/journal.pone.0153727/
44. McDunn JE, Li Z, Adam K-P, et al. Metabolomic signatures of aggressive prostate The Prostate 2013; 73 (14): 1547–60. doi: 10.1002/pros.22704.
45. Aff onti HC, Rowsam AM, Pellerite AJ, et al. Pharmaco- logical polyamine catabolism upregulation with methionine salvage pathway inhibition as an effective prostate cancer Nat Commun 2020; 11 (1): 52–67. doi: 10.1038/ s41467-019-13950-4/
46. Sun L, Yang J, Qin Y, et al. Discovery and antitumor evaluation of novel inhibitors of spermine oxidas J Enz Inhib Med Chem 2019; 34 (1): 1140–51. doi: 10.1080/14756366. 2019.1621863.
47. Peng Q, Wong CY-P, Cheuk IW-y, et al. The emerging clini- cal role of spermine in prostate Int J Mol Sci 2021; 22: 4382–402. doi: 10.3390/ij 94382.
48. Battaglia V, DeStefano Shields C, Murray-Stewart T, et al. Polyamine catabolism in carcinogenesis: potential targets for chemotherapy and chemopreve Amino Acids 2014; 46 (3): 511–9. doi: 10.1007/s00726-013-1529-6.
49. Bentrad VV, Zaletok SP, Klenov OO, et al. Expression of genes encoding polyamine enzymes in malignant and be- nign tumors of the human prostate. Oncology 2020; 22 (1–2): 32−5. doi: 32471/oncology.2663-7928.t-22-1- 2020-g.8739.
50. Giskeødegård GF, Bertilsson H, Selnæs KM, et al. Sper- mine and citrate as metabolic biomarkers for assessing pros- tate cancer aggressiven PLoS One 2013; 8 (4): e62375. doi: 10.1371/journal.pone.0062375.
51. Braadland PR, Giskeødegård G, Sandsmark E, et al. Ex vivo metabolic fingerprinting identifies biomarkers predictive of prostate cancer recurrence following radical prostatectomy. Br J Canc 2017; 117: 1656–64. doi: 1038/bjc.2017.346.
52. Goodwin AC, Jadallah S, Toubaji A, et al. Increased spermine oxidase expression in human prostate cancer and prostatic intraepithelial neoplasia Prostate 2008; 68: 766–72. doi: 10.1002/pros.20735.